| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$783,343 ) |
| | 2024 | 2022 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 000 | 6 | NIH | 2/14/2024 | -$209,734 |
| | 2024 | 2022 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 000 | 2 | NIH | 1/19/2024 | -$426,581 |
| | 2024 | 2022 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 000 | 3 | NIH | 1/19/2024 | -$13,387 |
| | 2024 | 2022 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 000 | 3 | NIH | 1/19/2024 | -$41,905 |
| | 2024 | 2021 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R42AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 000 | 5 | NIH | 1/19/2024 | -$65,953 |
| | 2024 | 2021 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R41AI152745 | Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses | 000 | 2 | NIH | 3/26/2024 | -$2 |
| | 2024 | 2021 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 000 | 5 | NIH | 1/19/2024 | -$8,300 |
| | 2024 | 2021 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R01AI126587 | Evolution of anti-filovirus B cell responses and mechanisms of protection | 000 | 5 | NIH | 1/29/2024 | -$17,482 |
| | 2024 | 2020 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R41AI147929 | Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein | 000 | 2 | NIH | 10/18/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = -$996,742 ) |
| | 2023 | 2022 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 000 | 6 | NIH | 5/10/2023 | $0 |
| | 2023 | 2022 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 000 | 2 | NIH | 4/21/2023 | $0 |
| | 2023 | 2022 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 000 | 3 | NIH | 4/26/2023 | -$380,000 |
| | 2023 | 2022 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 000 | 3 | NIH | 4/25/2023 | $0 |
| | 2023 | 2021 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R42AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 000 | 5 | NIH | 5/26/2023 | -$315,000 |
| | 2023 | 2021 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 000 | 5 | NIH | 4/20/2023 | -$300,000 |
| | 2023 | 2020 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R43AI136143 | ISTAb- A novel therapy to target staphylococcal toxins at the site of infections | 000 | 2 | NIH | 6/20/2023 | $0 |
| | 2023 | 2020 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R43AI145480 | Mining natively paired macque antibodies for Marburg virus protective antibodies | 000 | 2 | NIH | 6/20/2023 | -$1,742 |
| | 2023 | 2018 | INTEGRATED BIOTHERAPEUTICS, LLC | 4 RESEARCH CT STE 300 | ROCKVILLE | MD | 20850-3855 | MONTGOMERY | USA | R42AI122403 | Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease | 000 | 3 | NIH | 11/23/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $5,333,363 ) |
| | 2022 | 2022 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 000 | 3 | NIH | 2/24/2022 | $727,487 |
| | 2022 | 2022 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 000 | 2 | NIH | 3/22/2022 | $1,000,000 |
| | 2022 | 2022 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 000 | 6 | NIH | 3/14/2022 | $702,876 |
| | 2022 | 2022 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 000 | 3 | NIH | 3/15/2022 | $731,360 |
| | 2022 | 2020 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R41AI147929 | Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein | 000 | 2 | NIH | 6/2/2022 | $0 |
| | 2022 | 2019 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 003 | 5 | NIH | 9/8/2022 | $761,761 |
| | 2022 | 2019 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R43AI136229 | Remodeled glycoprotein for broad protection against ebolaviruses | 000 | 2 | NIH | 10/14/2021 | -$116 |
| | 2022 | 2019 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 001 | 1 | NIH | 9/26/2022 | $0 |
| | 2022 | 2018 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 002 | 4 | NIH | 9/8/2022 | $775,672 |
| | 2022 | 2018 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R42AI122403 | Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease | 000 | 3 | NIH | 1/28/2022 | -$123,788 |
| | 2022 | 2018 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R41AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 000 | 2 | NIH | 9/23/2022 | $1 |
| | 2022 | 2017 | INTEGRATED BIOTHERAPEUTICS INC | 4 RESEARCH CT | POTOMAC | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 001 | 3 | NIH | 9/8/2022 | $758,111 |
|
| Issue Date FY: 2021 ( Subtotal = $2,252,841 ) (Continued on the next page) |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 000 | 5 | NIH | 5/26/2021 | $1,186,705 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 001 | 2 | NIH | 9/27/2021 | $0 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 000 | 2 | NIH | 2/23/2021 | $745,628 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R41AI152745 | Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses | 001 | 2 | NIH | 6/10/2021 | $291,845 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 000 | 1 | NIH | 5/11/2021 | $1,000,000 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 001 | 2 | NIH | 4/8/2021 | $804,193 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R42AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 000 | 5 | NIH | 6/11/2021 | $978,271 |
| | 2021 | 2021 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI126587 | Evolution of anti-filovirus B cell responses and mechanisms of protection | 000 | 5 | NIH | 4/14/2021 | $733,183 |
| | 2021 | 2020 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R41AI152745 | Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses | 000 | 1 | NIH | 5/4/2021 | $0 |
| | 2021 | 2019 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 000 | 1 | NIH | 2/16/2021 | -$102 |
| | 2021 | 2019 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI136229 | Remodeled glycoprotein for broad protection against ebolaviruses | 003 | 2 | NIH | 9/2/2021 | $299,186 |
| | 2021 | 2019 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI136229 | Remodeled glycoprotein for broad protection against ebolaviruses | 001 | 2 | NIH | 9/2/2021 | -$299,186 |
| | 2021 | 2019 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 004 | 5 | NIH | 7/6/2021 | -$761,776 |
| | 2021 | 2018 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 003 | 4 | NIH | 7/6/2021 | -$775,672 |
| | 2021 | 2018 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI136229 | Remodeled glycoprotein for broad protection against ebolaviruses | 002 | 1 | NIH | 9/2/2021 | $302,469 |
| | 2021 | 2018 | INTEGRATED BIOTHERAPEUTICS, INC. | 4 RESEARCH COURT, SUITE 300 | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI136229 | Remodeled glycoprotein for broad protection against ebolaviruses | 000 | 1 | NIH | 9/2/2021 | -$302,469 |
|
